Synthetic Peptide
Human DR5 (residues 255-270) Synthetic Peptide, PEP-048, from Invitrogen.
DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified death domain containing receptor for TRAIL, which mediates TRAIL induced apoptosis. DR5 is a member of the TNF-receptor superfamily, and contains an intracellular death domain. DR5 can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by DR5. Two transcript variants encoding different isoforms of DR5 and one non-coding transcript have been found. Overexpression of DR5 induces apoptosis and activates NF-kappa-B. DR5 is expressed in a number of cell types, and to particularly high levels in lymphocytes and spleen. Diseases associated with DR5 dysfunction include squamous cell carcinoma, and diffuse infiltrative lymphocytosis syndrome.
| Marque | Invitrogen |
|---|---|
| Réf. B-LABO | BL-RE-175638 |
| Réf. fabricant | 11504710 |
| Gene ID (Entrez) | 8795 |
| Espèces | Human |
| Méthode de purification | purified |
| Numéro d’adhésion | O14763 |
| Nom usuel | Human DR5 (aa 255-270) |
| Concentration | 0.5 mg/mL |
| Contenu et stockage | -20°C. Avoid freeze-thaw cycles. |
| Format | Lyophilized |
| Formule | peptide with no preservative |
| À utiliser avec (application) | Control |
| Symbole de gène(s) | TNFRSF10B |
| Lyophilisé | Lyophilized |
| Conservateur | No preservative |
| Type de produit | Peptide |
| Quantité | 50 μg |
| État réglementaire | RUO - research use only |
| Séquence | C - V255 - P - E - Q - E - M - E - V - Q - E - P - A - E - P - T - G270 |
